CR20150092A - Derivados de diazepinona útiles para el tratamiento del síndrome x frágil, enfermedad de parkinson o enfermedad del reflujo - Google Patents
Derivados de diazepinona útiles para el tratamiento del síndrome x frágil, enfermedad de parkinson o enfermedad del reflujoInfo
- Publication number
- CR20150092A CR20150092A CR20150092A CR20150092A CR20150092A CR 20150092 A CR20150092 A CR 20150092A CR 20150092 A CR20150092 A CR 20150092A CR 20150092 A CR20150092 A CR 20150092A CR 20150092 A CR20150092 A CR 20150092A
- Authority
- CR
- Costa Rica
- Prior art keywords
- disease
- parkinson
- fragile
- syndrome
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La invención se refiere a un compuesto de la fórmula (I) o a una sal del mismo, en donde los sustituyentes son como se definen en la memoria descriptiva; a su preparación, a su uso como un medicamento, y a los medicamentos que lo comprenden.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1215033.0A GB201215033D0 (en) | 2012-08-23 | 2012-08-23 | Diazepinone derivatives |
PCT/IB2013/056782 WO2014030128A1 (en) | 2012-08-23 | 2013-08-21 | Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20150092A true CR20150092A (es) | 2015-05-04 |
Family
ID=47045285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20150092A CR20150092A (es) | 2012-08-23 | 2015-02-23 | Derivados de diazepinona útiles para el tratamiento del síndrome x frágil, enfermedad de parkinson o enfermedad del reflujo |
Country Status (44)
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201215033D0 (en) | 2012-08-23 | 2012-10-10 | Novartis Ag | Diazepinone derivatives |
WO2019025931A1 (en) | 2017-07-31 | 2019-02-07 | Novartis Ag | USE OF A MUSSEL FOR REDUCING THE USE OF COCAINE OR FOR PREVENTING A RECHUTE IN THE USE OF COCAINE |
CN113301894A (zh) * | 2019-01-29 | 2021-08-24 | 诺华股份有限公司 | mGluR5拮抗剂用于治疗阿片类物质镇痛耐受性的用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3853851A (en) * | 1972-01-26 | 1974-12-10 | Ciba Geigy Corp | Diazepinoisoquinolines |
GB0128996D0 (en) | 2001-12-04 | 2002-01-23 | Novartis Ag | Organic compounds |
AU2004226450A1 (en) * | 2003-03-26 | 2004-10-14 | Merck & Co. Inc. | Benzamide modulators of metabotropic glutamate receptors |
GB0413605D0 (en) * | 2004-06-17 | 2004-07-21 | Addex Pharmaceuticals Sa | Novel compounds |
TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
CU20090172A6 (es) | 2009-10-09 | 2011-10-05 | Facultad De Quimica Universidad De La Habana | Sistemas tricíclicos y tetracíclicos con actividad sobre el sistema nervioso central y vascular |
US8772301B2 (en) * | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
WO2012153796A1 (ja) | 2011-05-10 | 2012-11-15 | 協和発酵キリン株式会社 | ピリミドジアゼピノン化合物 |
GB201215033D0 (en) | 2012-08-23 | 2012-10-10 | Novartis Ag | Diazepinone derivatives |
-
2012
- 2012-08-23 GB GBGB1215033.0A patent/GB201215033D0/en not_active Ceased
-
2013
- 2013-08-21 MY MYPI2014003502A patent/MY170103A/en unknown
- 2013-08-21 RS RS20180581A patent/RS57231B1/sr unknown
- 2013-08-21 MX MX2015002367A patent/MX365253B/es active IP Right Grant
- 2013-08-21 ES ES13783671.4T patent/ES2672737T3/es active Active
- 2013-08-21 UA UAA201413654A patent/UA114326C2/uk unknown
- 2013-08-21 CN CN201380042195.XA patent/CN104520298B/zh active Active
- 2013-08-21 EP EP13783671.4A patent/EP2888259B1/en active Active
- 2013-08-21 EA EA201590415A patent/EA029493B1/ru not_active IP Right Cessation
- 2013-08-21 SI SI201331027T patent/SI2888259T1/en unknown
- 2013-08-21 NZ NZ703628A patent/NZ703628A/en not_active IP Right Cessation
- 2013-08-21 TR TR2018/07174T patent/TR201807174T4/tr unknown
- 2013-08-21 LT LTEP13783671.4T patent/LT2888259T/lt unknown
- 2013-08-21 CA CA2878564A patent/CA2878564C/en active Active
- 2013-08-21 AP AP2014008140A patent/AP2014008140A0/xx unknown
- 2013-08-21 BR BR112015003281A patent/BR112015003281A8/pt active Search and Examination
- 2013-08-21 WO PCT/IB2013/056782 patent/WO2014030128A1/en active Application Filing
- 2013-08-21 PT PT137836714T patent/PT2888259T/pt unknown
- 2013-08-21 AU AU2013307239A patent/AU2013307239B2/en not_active Ceased
- 2013-08-21 SG SG10201701333WA patent/SG10201701333WA/en unknown
- 2013-08-21 PL PL13783671T patent/PL2888259T3/pl unknown
- 2013-08-21 MA MA37849A patent/MA37849A1/fr unknown
- 2013-08-21 PE PE2015000245A patent/PE20150401A1/es active IP Right Grant
- 2013-08-21 SG SG11201500068QA patent/SG11201500068QA/en unknown
- 2013-08-21 NO NO13783671A patent/NO2888259T3/no unknown
- 2013-08-21 JP JP2015527996A patent/JP6169699B2/ja not_active Expired - Fee Related
- 2013-08-21 HU HUE13783671A patent/HUE037971T2/hu unknown
- 2013-08-21 DK DK13783671.4T patent/DK2888259T3/en active
- 2013-08-21 KR KR1020157003903A patent/KR102104149B1/ko active IP Right Grant
- 2013-08-22 US US13/973,454 patent/US8853203B2/en active Active
- 2013-08-22 UY UY0001034986A patent/UY34986A/es unknown
- 2013-08-22 TW TW102130096A patent/TWI616444B/zh not_active IP Right Cessation
- 2013-08-22 JO JOP/2013/0250A patent/JOP20130250B1/ar active
- 2013-08-23 AR ARP130102989A patent/AR092212A1/es not_active Application Discontinuation
-
2014
- 2014-08-19 US US14/462,813 patent/US9284331B2/en active Active
- 2014-12-18 ZA ZA2014/09345A patent/ZA201409345B/en unknown
- 2014-12-19 TN TN2014000528A patent/TN2014000528A1/fr unknown
-
2015
- 2015-02-02 IL IL237062A patent/IL237062A/en active IP Right Grant
- 2015-02-20 CL CL2015000416A patent/CL2015000416A1/es unknown
- 2015-02-20 PH PH12015500373A patent/PH12015500373A1/en unknown
- 2015-02-23 CR CR20150092A patent/CR20150092A/es unknown
- 2015-02-23 GT GT201500039A patent/GT201500039A/es unknown
- 2015-02-23 CU CUP2015000016A patent/CU20150016A7/es unknown
- 2015-07-02 HK HK15106284.5A patent/HK1206008A1/xx not_active IP Right Cessation
-
2016
- 2016-02-12 US US15/042,924 patent/US9650377B2/en active Active
-
2017
- 2017-04-28 US US15/581,642 patent/US20170305903A1/en not_active Abandoned
- 2017-06-28 JP JP2017125822A patent/JP2017226661A/ja not_active Withdrawn
-
2018
- 2018-05-29 HR HRP20180850TT patent/HRP20180850T1/hr unknown
- 2018-06-07 CY CY181100599T patent/CY1120728T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
CR20150326A (es) | Inhibidores de autotaxina | |
CU20140048A7 (es) | Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos | |
CO6781507A2 (es) | Novedosos derivados heterociclicos | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
UY33541A (es) | N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas | |
DOP2015000157A (es) | Lactamas fusionadas de arilo y heteroarilo | |
ECSP12012065A (es) | Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos | |
BR112016026291A2 (pt) | Derivados do ácido borônico e usos terapêuticos dos mesmos | |
ECSP14026138A (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
EA201591624A1 (ru) | Новые производные пиразола | |
UY34955A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
DOP2015000076A (es) | Benzamidas | |
CU20150061A7 (es) | PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACIÓN SIN SENTIDO | |
CO7170173A2 (es) | Derivados de carbamato/urea | |
ECSP16096831A (es) | Derivados de naftiridinadiona | |
UY35745A (es) | Derivados sustituidos de fenilalanina | |
UY35602A (es) | Compuestos nuevos para el tratamiento del cáncer | |
PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
UY35785A (es) | Derivados de piperazina sustituidos como moduladores del transportador de la glicina-1 (glyt1) | |
UY31646A1 (es) | Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico | |
CR20150092A (es) | Derivados de diazepinona útiles para el tratamiento del síndrome x frágil, enfermedad de parkinson o enfermedad del reflujo | |
GT201500189A (es) | Inhibidores de autotaxina | |
CU20130108A7 (es) | Novedosos derivados heterocíclicos |